Recruiting

The Impact of Radiotherapy on Oligometastatic Cancer

ClinicalTrials.gov IDNCT05933876

PhaseNot Applicable

Enrollment2000

SponsorInstitut Investigacio Sanitaria Pere Virgili

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer

About this study

Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.

Interventions

Diagnostic Test: To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR). — Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
Diagnostic Test: To propose a diagnostic test to determine the effectiveness of SABR. — Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
Diagnostic Test: To propose a diagnostic test for Oligometastatic Cancer (OC). — Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.

Primary outcomes

Radiological rate (3 months after treatment)
Progression-Free Survival (5 years after treatment)
SABR toxicities (5 years after treatment)

Eligibility information

Inclusion Criteria: * Histologic confirmation of primary tumor: breast, prostate, lung, colorectal. * 18 years old or older. * Up to five metastases located in the bone, lung, node, liver or brain. * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1. Exclusion Criteria: * Non-melanoma skin cancer. * Previous radiotherapy in the same anatomic location. * Presence of vascular collagen disease. * Pregnancy or lactation at the time of inclusion.

Study locations

Complejo Hospitalario Universitario Albacete, Albacete, Albacete Spain
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona Spain
Hospital Universitari Vall d'Hebron, Barcelona, Barcelona Spain
Institut Català d'Oncologia, Barcelona, Barcelona Spain
Hospital Universitario Virgen de las Nieves, Granada, Granada Spain
Hospital Universitari Arnau de Vilanova, Lleida, Lleida Spain
Hospital de La Luz, Madrid, Madrid Spain
Hospital Ruber Internacional, Madrid, Madrid Spain
Hospital Universitario HM Sanchinarro, Madrid, Madrid Spain
Hospital Universitario Quirónsalud, Madrid, Madrid Spain

Showing 10 of 21 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.